

LifeGenes™ Genetic Profile Report References

Your Genetic Profile Analysis and Report has been prepared by Valin Reja PhD, Molecular Biologist (Excelgene).

All references relating to your Genetic Profile Analysis and Report and The LifeGenes™ Program can be reviewed by going to www.lifegenes.com.au/programreferences

Disclaimer

All rights reserved. No parts of this Genetic Profile Report may be reproduced in any form or by means – graphics, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems – without the written permission of the publisher.

Products that are referred to in this document may be either trademarks and/or registered trademarks of the respective owners. The publisher and the author make no claim to these trademarks.

While every precaution has been taken in the preparation of this document, the publisher and the author assume no responsibility for errors or omissions, or for damages resulting from the use of information contained in this document. In no event shall the publisher and the author be liable for any loss of profit, any commercial or personal damage caused or alleged to have been caused directly or indirectly by this document.

© Excelgene Pty Ltd 2008

LifeGenes™ Genetic Profile Report References

Analysis prepared by Valin Reja PhD, Molecular Biologist (Excelgene)

HIF-1 References

1. Mortimer H, Patel S, Peacock AJ. The genetic basis of high-altitude pulmonary oedema. *Pharmacol. Ther.* 2004; 101: 183-192.
2. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. *Carcinogenesis.* 2003; 24: 1779-1783.
3. Suzuki K, Kizaki T, Hitomi Y, Nukita K, Miyazawa N, Koayashi K, Ohnuki Y, Ohno H. Genetic variation in hypoxia-inducible factor 1alpha and its possible association with high altitude adaptation in Sherpas. *Medical Hypoth.* 2003; 61: 385-389.
4. Prior SJ, Hagberg JM, Phares DA, et al. Sequence variation in hypoxia-inducible factor 1alpha (HIF1A): association with maximal oxygen consumption. *Physiol. Genomics.* 2003; 15: 20-26.
5. Raguso CA, Guinot SL, Janssens JP, Kayser B, Pichard C. Chronic hypoxia: common traits between chronic obstructive pulmonary disease and altitude. *Curr. Opin. Clin. Nutr. Metab. Care.* 2004; 7: 411-417.
6. Suzuki K, Kizaki T, Hitomi Y, Nukita M, Kimoto K, Miyazawa N, Kobayashi K, Ohnuki Y, Ohno H. genetic variation in hypoxia-inducible factor 1 α and its possible association with high altitude adaptation in Sherpas. *Medical Hypotheses.* 2003; 61: 385-389.
7. Pouyssegur J, Dayan F, Mazure N. Hypoxia signaling in cancer and approaches to enforce tumour regression. *Nature.* 2006 : 437-443.
8. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. *Carcinogenesis.* 2003; 24: 1779-1983.
9. Raguso C, Guinot S, Janssens J, Kayser B, Pichard C. Chronic hypoxia; common traits between chronic obstructive pulmonary disease and altitude. *Curr Opin Clin Nutr Metab Care.* 2004; 7: 411-417.

MTHFR References

1. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from Mendelian randomisation. *Lancet.* 2005; 365: 224-232.
2. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677 C→T polymorphism and risk of coronary heart disease. *JAMA.* 2002; 288: 2023-2031.
3. Yilmaz H, Isbir S, Agachan B, Ergen A, Farsak B, Isbir T. C677T mutation of methylenetetrahydrofolate reductase gene and serum homocysteine levels in Turkish patients with coronary artery disease. *Cell Biochem. Funct.* 2005.

4. Sun J, Xu Y, Xue J, Zhu Y, Lu H. Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. *Mol. Cell Endocrinol.* 2005; 229: 95-101.
5. Liu CS, Chiang HC, Chen HW. Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. *Nutrition.* 2004; 20: 974-978.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from meta-analysis. *BMJ.* 2002; 325: 1-7.
7. Klerk M, Verhoef P, Clarke R, Blom H, Kok F, Schouten E and the MTHFR Studies Collaboration Group. T Polymorphism and Risk of Coronary Heart Disease. *Health Module.* 2002; 288 16: 2023-2031.
8. Liu C, Chiang H, Chen H. Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. *Nutrition.* 2004; 20: 974-978.
9. Sun J, Xu Y, Xue J, Zhu Y, Lu H. Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. *Mol Cell Endocrinol.* 2005; 229: 95-101.
10. Casas J, Bautista L, Smeeth L, Sharma P, Hingorani A. Homocysteine and stroke: evidence on a casual link from mendelian randomisation. *Lancet.* 2005; 365: 194-196.
11. Yilmaz H, Isbir S, Agachan B, Ergen A, Farsak B, Isbir T. C677T mutation of methylenetetrahydrofolate reductase gene at serum homocysteine levels in Turkish patients with coronary artery disease. *Cell Biochem Funct.* 2005.
12. Wald D, Law M, Morris J. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ.* 2002; 325: 1-7.

ACE References

1. Lin M-H, Tseng C-H, Tseng C-C, Huang C-H, Chong C-K, Tseng C-P. Real-time PCR for rapid genotyping of angiotensin-converting enzyme insertion/deletion polymorphism. *Clin. Biochem.* 2001; 34: 661-666.
2. Myerson S, Hemingway H, Budget R, Martin J, Humphries S, Montgomery H. Human angiotensin I-converting enzyme gene and endurance performance. *J. Appl. Physiol.* 1999; 87: 1313-1316.
3. Gayagay G, Yu B, Hambly B, et al. Elite endurance athletes and the ACE I allele: the role of genes in athletic performance. *Hum. Genet.* 1998; 103: 48-50.
4. Friedl W, Krempler F, Sanderhfer F, Paulweber B. Insertion/deletion polymorphism in the angiotensin-converting-enzyme gene and blood pressure during ergometry in normal males. *Clin. Genet.* 1996; 50: 541-544.
5. Kanazawa H, Okamoto T, Hirata K, Yoshikawa J. Deletion polymorphism in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2000; 162: 1235-1238.
6. Folland J, Leach B, Little T, et al. Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload. *Exp. Physiol.* 2000; 85: 575-579.

ENOS-3 References

1. Ghilardi G, Biondi ML, DeMonti M, Bernini M, Turri O, Massaro F, Guagnellini E, Scorza R. Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthase gene. *Clin. Chem.* 2002; 48: 989-993.
2. Data SA, Roltsch MH, Hand B, Ferrell RE, Park J-J, Brown MD. eNOS T-786C genotype, physical activity, and peak forearm blood flow in females. *Medicine Sci. Sports Exerc.* 2003: 1991-1997.
3. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Ogawa H, Kugiyama K. T → 786C mutation in the 5' flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. *Am. J. Cardiol.* 2000; 86: 628-634.
4. Erbs S, Baithier Y, Linke A, et al. Promoter but not exon 7 polymorphism of endothelial nitric oxide synthase affects training-induced correction of endothelial dysfunction. *Arterioscler. Thromb. Vasc. Biol.* 2003; 23: 1814-1819.
5. Kimura T, Yokoyama T, Matsumura Y, et al. NOS3 genotype-dependent correlation between blood pressure and physical activity. *Hypertension.* 2003; 41: 355-360.
6. Wang XL, Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. *Mol. Genet. Metab.* 2000; 70: 241-251.
7. Rossi GP, Taddei S, Virdis A, et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of caucasian hypertensive patients. *JACC.* 2003; 41: 938-945.
8. Data S, Roltsch M, Hand B, Ferrell R, Park J, Brown M. ENox T-786C Genotype, Physical Activity, and Peak Forearm Blood Flow In Females. *Medicine 7 Science in Sports & Exercise.* 2003: 1991-1997.
9. Dakak N, Husain S, Mulcahy D, Andrews N, Panza J, Waclawiw M, Schenke W, Quyyumi A. Contribution of Nitric Oxide to Reactive Hyperemia. Impact of Endothelial Dysfunction. *Hypertension.* 1998; 32: 9-15.

ADRβ-2 References

1. Large V, Hellstrom L, Reynisdottir S, Lonngqvist F, Eriksson P, Lannfelt L, Arner P. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. *J. Clin. Invest.* 1997; 100: 3005-3013.
- 2.
3. Meirhaeghe A, Helbecque N, Cottel D, Amouyel P. Bete2-adrenoceptor gene polymorphism, body weight, and physical activity. *Lancet.* 1999; 353: 896.
4. Moore GE, Shuldiner AR, Zmuda JM, Ferrell RE, McCole SD, Hagberg JM. Obesity gene variant and elite endurance performance. *Metabolism.* 2001; 50: 1391-1392.
5. Garnec C, Perusse L, Chagnon YC, Rankinen T, Gagnon J, Borecki IB, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C. Effects of B2-adrenergic receptor gene variants on adiposity: The HERITAGE Family Study. *Obes. Res.* 2003; 11: 612-618.
6. Gonzalez Sanchez JL, Proenza AM, Martinez Larrad MT, Ramis JM, Fernandez Perez C, Palou A, Serrano Rio M. The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. *Clin. Endocrinol.* 2003; 59: 476-481.

7. Macho-Azcarate T, Marti A, Calabuig J, Martinez JA. Basal fat oxidation and after a peak oxygen consumption test in obese women with beta2 adrenoceptor gene polymorphism. *J. Nutr. Biochem.* 2003; 14: 275-279.
8. Perusse L, Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Snyder EE, Bouchard C. The human obesity gene map: the 2004 update. *Obes. Res.* 2005; 13: 381-490.
9. Williams CM. Lipid metabolism in women. *Proceedings Nutrition Society.* 2004; 63: 153-160.
10. Ukkola O, Tremblay A, Bouchard C. Beta-2 adrenergic receptor variants are associated with subcutaneous fat accumulation in response to long-term overfeeding. *Int. J. Obes. Relat. Metab. Disord.* 2001; 25: 1604-1608.
11. Macho-Azcarate T, Calabuig J, Marti A, Martinez JA. A maximal effort trial in obese women carrying the beta2-adrenoceptor Gln27Glu polymorphism. *J. Physiol. Biochem.* 2002; 58: 103-108.
12. Collins S, Cao W, Robidoux J. Learning New Tricks from Old Dogs: β -Adrenergic Receptors Teach New Lessons on Firing Up Adipose Tissue Metabolism. *Molecular Endocrinology.* 2004; 18: 2123-2131.
13. Large V, Hellström L, Reynisdóttir S, Lönnqvist F, Eriksson P, Lannfelt I, Arner P. Human Beta-2 Adrenoceptor Gene Polymorphisms Are Highly Frequent in Obesity and Associate with Altered Adipocyte Beta-2 Adrenoceptor Function. *J. Clin. Invest.* 1997; 100: 3005-3013.
14. Williams C. Lipid metabolism in women. *Nutrition Society.* 2004; 63: 153-160.
15. Moore G, Shuldiner A, Zmuda J, Ferrell R, McCole S, Hagberg J. Obesity Gene Variant and Elite Endurance Performance. *Metabolism.* 2001; 50: 1391-1392.
16. Sánchez J, Proenzat A, Larrad M, Ramist J, Pérez C, Palout A, Ríos M. The glutamine 27 glutamic acid polymorphism of the β 2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. *Clinical Endocrinology.* 2003; 59: 476-481.
17. Phares D, Halverstadt A, Shuldiner A, Ferrell R, Douglass L, Ryan A, Goldberg A, Hagberg J. Association Between Body Fat Response to Exercise Training and Multilocus ADR Genotypes. *Obesity Research.* 2004; 12: 807-815.
18. Masuo K, Katsuya T, Kawaguchi H, Fu Y, Rakugi H, Ogihara T, Tuck M. beta (2) – Adrenoceptor Polymorphisms Relate to Obesity Through Blunted Leptin-Mediated Sympathetic Activation. *Am J Hypertens.* 2006; 19: 1084-1091.
19. Gonzalez Sanchez J, Proenza A, Martinez Larrad M, Ramis J, Fernandez Perez C, Palou A, Serrano Rios M. The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. *Clin Endocrinol (oxf).* 2003; 59: 476-481.
20. Macho-Azcarate T, Marti A, Calabuig J, Martinez J. Basal fat oxidation and after a peak oxygen consumption test in obese women with a beta2 adrenoceptor gene polymorphism. *J Nutr Biochem.* 2003; 14: 275-279.
21. Macho-Azcarate T, Calabuig J, Marti A, Martinez J. A maximal effort trial in obese women carrying the beta2-adrenoceptor Gin27Glu polymorphism. *J Physiol Biochem.* 2002; 58: 103-108.
22. Moore G, Shuldiner A, Amuda J, Ferrell R, McCole S, Hagberg J. Obesity gene variant and elite endurance performance. *Metabolism.* 2001; 50: 1391-1392.

Col1A1 References

1. McKenna MJ, Nguyen-Huynh AT, Kristiansen AG. Association of otosclerosis with Sp1 binding site polymorphism in Col1A1 gene: evidence for a shared genetic etiology with osteoporosis. *Otology Neurotology*. 2004; 25: 447-450.
2. Long JR, Liu PY, Lu Y, Xiong DH, Zhao LJ, Zhang YY, Elze L, Deng HW. Association between Col1A1 gene polymorphisms and bone in Caucasians. *Eur. J. Hum. Genet.* 2004; 12: 383-388.
3. Garcia-Giralt N, Nogues X, Enjuanes A, Puig J, Mellibovsky L, Bay-Jensen A, Carreras R, Balcells S, Diez-Perez A, Grinberg D. Two new single-nucleotide polymorphisms in the Col1A1 upstream regulatory region and their relationship to bone mineral density. *J. Bone Miner. Res.* 2002; 17: 384-393.
4. Liu P-Y, Lu Y, Long J-R, Xu F-H, Shen H, Recker RR, Deng H-W. Common variants at the PCOL2 and Sp1 binding sites of the Col1A1 gene and their interactive effect influence bone mineral density in Caucasians. *J. Med. Genet.* 2004; 41: 752-757.
5. Mann V, Hobson EE, Li B, Stewart TL, Grant SFA, Robins SP, Aspden RM, Ralston SH. A Col1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. *J. Clin. Invest.* 2001; 107: 899-907.
6. Bandres E, Pombo I, Gonzalez-Huarriz M, Rebollo A, Lopez G, Garcia-Foncillas J. Association between bone mineral density and polymorphisms of the VDR, ER-alpha, Col1A1 and CTR genes in Spanish postmenopausal women. *J. Endocrinol. Invest.* 2005; 28: 312-321.
7. Tilkeridis C, Bei T, Garantiotis S, Stratakis CA. Association of a Col1A1 polymorphism with lumbar disc disease in young military recruits. *J. Med. Genet.* 2005; 42: e44.
8. Van Pttelbergh I, Goemaere S, Nuytinck L, De Paepe A, Kaufman JM. Association of the type I collagen alpha 1 Sp1 polymorphism, bone density and upper limb muscle strength in community-dwelling elderly men. *Osteoporos. Int.* 2001; 12: 895-901.
9. Mann V, Ralston SH. Meta-analysis of Col1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. *Bone.* 2003; 32: 711-717.
10. Long J, Lui P, Lu Y, Xiong D, Zhao L, Ahang Y, Elze L, Rec R, Deng H. Association between COL1A1 gene polymorphisms and bone in Caucasians. *Eur J Hum Genet.* 2004;12: 383-388.
11. Garcia-Giralt N, Nogues X, Enjuanes A, Puig J, Mellibovsky L, Bay-Jensen A, Carreras R, Balcells S, Diez-Perez A, Geinberg D. Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density. *J Bone Miner Res.* 2002; 17: 384-393.
12. Lian K, Zmuda J, Nevitt M, Lui L, Hochberg M, Greene D, Li J, Wang J, Lane N. Type 1 collagen alpha1 Sp1 transcription factor binding site polymorphism is associated with reduced risk of hip osteoarthritis defined by severe joint space narrowing in elderly women. *Arthritis Rheum.* 2005; 52: 1431-1436.
13. Garcia-Giralt N, Nogués X, Enjuanes A, Puig J, Mellibovsky L, Bay-Jensen A, Carreras R, Balcells S, Díez-Pérez A, Grinberg D. Two New Single-Nucleotide Polymorphisms in the COL1A1 Upstream Regulatory Region and Their Relationship to Bone Mineral Density. *JBMR.* 2002; 17: 384-393.
14. MacDonald H, McGuigan F, New S, Campbell M, Golden M, Ralston S, Reid D. COL1A1 Sp1 Polymorphism Predicts Perimenopausal and Early Postmenopausal Spinal Bone Loss. *J Bone Miner Res.* 2001; 16: 1634-1641.

15. Liu P, Lu Y, Long J, Xu F, Shen H, Recker R, Deng H. Common variants at the PCOL2 and Sp1 binding sites of the COL1A1 gene and their interactive effect influence bone mineral density in Caucasians. *J. Med. Genet.* 2004; 41: 752-757.
16. Louneva N, Saitta B, Herrick D, Jimenez S. Transcriptional Inhibition of Type 1 Collagen Gene Expression in Scleroderma Fibroblasts by the Antineoplastic Drug Ecteinascidin 743. *The Journal of Biological Chemistry.* 2003; 278: 40400-40407.
17. Kalajzic I, Terzic J, Rumboldt Z, Mack K, Naprta A, Ledgard F, Gronowicz G, Clark S, Rowe D. Osteoblastic Response to the Defective Matrix in the Osteogenesis Imperfecta Murine (oim) Mouse. *Endocrinology.* 2002; 143: 1594-1601.
18. McKenna M, Nguyen-Huynh A, Kristiansen A. Association of Otosclerosis With Sp1 Binding Site Polymorphism in COL1A1 Gene: Evidence for a Shared Genetic Etiology With Osteoporosis. *Otology & Neurotology.* 2004; 25: 447-450.
19. Mahonen A, Jukkola A, Risteli L, Risteli J, Maenpaa P. Type 1 procollagen synthesis is regulated by steroids and related hormones in human osteosarcoma cells. *J Cell Biochem.* 1998; 68: 151-163.
20. McKenna M, Nguyen-Huynh A, Kristiansen A. Association of otosclerosis with Sp1 binding site polymorphism in COL1A1 gene: evidence for a shared genetic etiology with osteoporosis. *Otol Neurotol.* 2004; 25: 447-450.
21. Bandres E, Pombo I, Gonzalez-Huarriz M, Rebollo A, Lopez G, Garcia-Foncillas J. Association between bone mineral density and polymorphisms of the VDR, ERalpha, COL1A1 and CTR genes in Spanish postmenopausal women. *J Endocrinol Invest.* 2005; 28: 312-321.
22. Tilkeridis C, Bei T, Garantziotis S, Stratakis C. Association of a COL1A1 polymorphism with lumbar disc disease in young military recruits. *J Med Genet.* 2005; 42.
23. Mann V, Ralston S. Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. *Bone.* 2003; 32: 711-717.
24. Cicchillitti L, Jimenez S, Sala A, Saitta B. B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with SP1 and CBF factors in scleroderma fibroblasts. *Biochem.* 2004; 378: 609-616.
25. Mann V, Hobson E, Li B, Stewart T, Grant S, Robins S, Aspden R, Ralston S. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. *J. Clin. Invest.* 2001; 107: 899-907.
26. Yamada Y, Ando F, Niino N, Shimokata H. Association of a -1997G-> T polymorphism of the collagen Ialpha1 gene with bone mineral density in postmenopausal Japanese women. *Hum Biol.* 2005; 77: 27-36.
27. Chen S, Artlett C, Jimenez S, Varga J. Modulation of human alpha1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro. *Gene.* 1998; 215: 101-110.
28. Hitraya E, Varga J, Artlett C, Jimenez S. Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. *Arthritis rheum.* 1998; 41: 2048-2058.
29. Artlett C, Chen S, Varga J, Jimenez S. Modulation of basal expression of the human alpha1(I) procollagen gene (COL1A1) by tandem NF-1/Sp1 promoter elements in normal human dermal fibroblasts. *Matrix Biol.* 1998; 17: 425-434.
30. Van Pottelbergh I, Goemaere S, Nuytinck L, De Paepe A, Kaufman J. Association of the type I collagen alpha1 Sp1 polymorphism, bone density and upper limb muscle strength in community-dwelling elderly men. *Osteoporos Int.* 2001; 12: 895-901.

31. Long J, Liu P, Lu Y, Xiong D, Zhao L, Ahang Y, Elze L, Recker R, Deng H. Association between COL1A1 gene polymorphisms and bone size in Caucasians. *Eur J hum Genet.* 2004; 12: 383-388.
32. Garcia-Giralt N, Enjuanes A, Bustamante M, Mellibovsky L, Nogues X, Carreras R, Diez-Perez A, Grinberg D, Balcells S. In vitro functional assay of alleles and haplotypes of two COL1A1-promoter SNPs. *Bone.* 2005; 36: 902-908.
33. Ferrari S, Rizzoli R. Gene variants for osteoporosis and their pleiotropic effects in aging. *Mol Aspects Med.* 2005; 26: 145-167.
34. Todhunter C, Sutherland-Craggs A, Bartram S, Donaldson P, Daly A, Francis R, Mansfield J, Thompson N. Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. *Gut.* 2005; 54: 1579-1584.

PPAR γ 2 References

1. Adamo KB, Sigal RJ, Williams K, Kenny G, Prudhomme D, Tesson F. Influence of Pro12Ala peroxisome proliferators-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes. *Diabetologia.* 2005; 48: 1503-1509.
2. Buzzetti R, Petrone A, Caiazzo AM, Alemanno I, Zavarella S, Capizzi M, Mein CA, Osborn JA, Vania A, Mario UD. PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity. *Pediatric Res.* 2005; 57: 138-140.
3. Vanttinen M, Nuutila P, Pihlajamaki J, Hallsten K, Virtanen KA, Lautala R, Peltoniemi P, Kempainen J, Takala T, Viljanen AP, Knuuti J, Laakso M. The effect of the Ala12 allele of the peroxisome proliferators-activated receptor-gamma2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study. *J. Clin. Endocrinol. Metab.* 2005; 90: 4249-4254.
4. Frederiksen L, Brodbeck K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA. Studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: Heterozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. *J Clin. Endocrinol. Metab.* 2002; 87: 3989-3992.
5. Dony AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH, Morris AD, Palmer CN. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to the Type 2 diabetes. *Diabetologia.* 2004; 47: 555-558.
6. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARG gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat. Genet.* 2000; 26: 76-80.
7. Arner P. Obesity and the Adipocyte: Regional adiposity in man. *J. Endocrinol.* 1997; 155: 191-192.
8. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARG gamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat. Genet.* 1998; 20: 284-287.
9. Shulman G. Cellular mechanisms of insulin resistance. *The Journal of Clinical Investigation.* 2000; 106: 171-176.
10. Arner P, Regional adiposity in man. *Journal of Endocrinology.* 1997; 155: 191-192.

11. Rodríguez, E, Ribot J, Rodríguez A, Palou A. PPAR- γ 2 Expression in Response to Cafeteria Diet: Gender- and Depot-Specific Effects. *Obesity Research*. 2004; 12: 1455-1463.
12. Staels B, Fruchart J. Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists. *Diabetes*. 2005; 54: 2460-2470.
13. Ostergard T, Ek J, Hamid Y, Saltin B, Pedersen O, Hansen T, Schmitz O. Influence of the PPAR-gamma2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects. *Horm Metab Res*. 2005; 37: 99-105.
14. Staels B, Fruchart J. Therapeutic roles of peroxisome proliferators-activated receptor agonists. *Diabetes*. 2005; 54: 2460-2470.
15. Robitaille J, Despres J, Perusse L, Vohl M. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. *Clin Genet*. 2003; 63: 109-116.
16. Karasaki Y, Kashiwazaki H. The difference of mutation in the peroxisome proliferators activated receptor gamma2 gene among people at high altitudes and low altitudes in Bolivia. *J UOEH*. 2005; 27: 243-248.
17. Doney A, Fischer B, Cecil J, Boylan K, McGuigan F, Ralston S, Morris A, Palmer C. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 Diabetes. *Diabetologia*. 2004; 47: 555-558.
18. Celi F, Shuldiner A. The role of peroxisome proliferators-activated receptor gamma in diabetes and obesity. *Curr Diab Rep*. 2002; 2: 179-185.
19. Vanttinen M, Nuutila P, Pihlajamaki J, Hallsten K, Virtanen K, Lautamaki R, Peltoniemi P, Kempainen J, Takala T, Viljanen A, Knuuti J, Laakso M. The effect of the Ala12 allele of the peroxisome proliferators-activated receptor-gamma2 gene on skeletal muscle glucose uptake depends on obesity: a positron emission tomography study. *J Clin Endocrinol Metab*. 2005; 90: 4249-4254.
20. Tavares V, Hirata R, Rodrigues A, Monte O, Salles J, Scalissi N, Speranza A, Hirata M. Association between Pro12Ala polymorphism of the PPAR gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. *Diabetes Obes Metab*. 2005; 7: 605-611.
21. Stumvoll M, Haring H. Insulin resistance and insulin sensitizers. *Horm Res*. 2001; 55: 3-13
22. Adamo K, Sigal R, Williams K, Kenny G, Prud'homme D, Tesson F. influence of Pro12Ala peroxisome proliferators-activated receptor gamma2 polymorphism on glucose response to exercise training in type 2 diabetes. *Diabetologia*. 2005; 48: 1503-1509.
23. Franks P, Luan J, Browne P, Harding A, O'Rahilly S, Chatterjee V, Wareham N. Does Peroxisome Proliferator-Activated Receptor γ Genotype (Pro12Ala) Modify the association of Physical Activity and Dietary Fat With Fasting Insulin Level. *Metabolism*; 2004; 53: 11-16.
24. Altshuler D, Hirschhorn J, Klannemark M, Lindgren C, Vohl M, Nemesh J, Lane C, Shaffner S, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson T, Daly M, Groop L, Lander E. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat Genet*. 2000; 26: 76-80.
25. Deeb S, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala Substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat Genet*. 1998; 20: 284-287.
26. Frederiksen L, Kasper Brodbeck K, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer S. Studies of the Pro12Ala Polymorphism of the PPAR- γ Gene in the Danish

MONICA Cohort: Homozygosity of the Ala Allele Confers a Decreased Risk of the Insulin Resistance Syndrome. *J Clin Endocrinol Metab.* 2002; 87: 3989-3992.

27. Beamer B, Yen C, Andersen R, Muller D, Elahi D, Cheskin L, Andres R, Roth J, Shuldiner A. Association of the Pro12Ala Variant in the Peroxisome Proliferator-Activated Receptor- γ 2 Gene With Obesity in Two Caucasian Populations. *Diabetes.* 1998; 47: 1806-1808.
28. Ailhaud G. Obesity and the Adipocyte. *Journal of Endocrinology.* 1997; 155: 201-202.
29. Pihlajamäki J, Vanhala M, Vanhala P, Laakso M. The Pro12Ala Polymorphism of the PPAR γ 2 Gene Regulates Weight from Birth to Adulthood. *Obesity Research.* 2004; 12: 187-190.
30. Ghossaini M, Meyre D, Lobbens S, Clément G, Charles M, Tauber M, Weill J. Implication of the Pro12Ala polymorphism of the PPAR γ 2 gene in type 2 diabetes and obesity in the French people. *BMC Med Genet.* 2005; 6: 11.

TNF α & IL-6 References

1. Neidhart M, Muller-Lander U, Frey W, Bosserhoff AK, Colombani PC, Frey-Rindova P, Hummel KM, Gay RE, Hauselmann H, Gay S. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. *Osteoarthritis Cartilage.* 2000; 8: 222-229.
2. Winchester EC, Millwood IY, Rand L, Penny MA, Kessler AM. Association of the TNF-alpha-308 (G \rightarrow A) polymorphism with self-reported history of childhood asthma. *Hum. Genet.* 2000; 107: 591-596.
3. Warren GL, Hulderman T, Jensen N, McKinsty M, Mishra M, Luster MI, Simeonova PP. Physiological role of tumor necrosis factor alpha in traumatic muscle injury. *FASEB Journal.* 2002; Aug 7.
4. Steinacker JM, Lormes W, Reissnecker S, Liu Y. New aspects of the hormone and cytokine response to training. *Eur. J. Appl. Physiol.* 2004; 91: 382-391.
5. Vignaud A, Cebrian J, Martelly I, Caruelle JP, Ferry A. Effect of anti-inflammatory and antioxidant drugs on the long-term repair of severely injured skeletal muscle. *Exp. Physiol.* 2005; 22.
6. Smith LL. Cytokine hypothesis of overtraining: a physiological adaptation excessive stress? *Med. Sci. Sports Exerc.* 2000; 32: 317-331.
7. Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen JN, Pedersen BK. A trauma-like elevation of plasma cytokines in humans in response to treadmill running. *J. Physiol.* 1998; 513: 889-894.
8. Gander M, Fischer J, Maly F, van Känel R. Effect of the G-308A polymorphism of the tumor necrosis factor (TNF)- α gene promoter site on plasma levels of TNF- α and C-reactive protein in smokers: a cross-sectional study. *Bmc Cardiovascular Disorders.* 2004; 4:17.
9. Huang S, Su C, Chang S. Tumor Necrosis Factor- α Gene Polymorphism in Chronic Bronchitis. *Am J Respir Crit Care Med.* 1997; 156: 1436-1439.
10. Gelfand E. Inflammation, Asthma, and Tumor Necrosis Factor-alpha. American Academy of Allergy, Asthma & Immunology 2007 Annual Meeting.

11. van den Berg W, Joosten L, Kollias G, van de Loo F. Role of tumour necrosis factor α in experimental arthritis: separate activity of interleukin 1β in chronicity and cartilage destruction. *Ann Rheum Dis.* 1999; 58: 140-148.
12. Warren G, Hulderman T, Jensen N, McKinstry M, Mishra M, Luster M, Simeonova P. Physiological role of tumor necrosis factor α in traumatic muscle injury. *The FASEB Journal.* 2002; 10.
13. Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, Pereira D, Moutinho J, Canedo P, Machado J, Medeiros R. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. *Biochem Biophys Res Commun.* 2005; 334: 588-592.
14. Winchester E, Millwood I, Rand L, Penny M, Kessling A. Association of the TNF-alpha-308 (G->A) polymorphism with self-reported history of childhood asthma. *Hum Genet.* 2000; 107: 591-596.
15. Mazaheri S, Hajilooi M, Rafiei A. The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with migraine without aura. *J Neurol.* 2006; 253: 1589-1593.
16. Sookoian S, González C, Pirola C. Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. *Obes Res.* 2005; 13: 2122-2131.
17. Saarela T, Hiltunen M, Helisalmi S, Heinonen S, Laakso M. Tumour necrosis factor-alpha gene haplotype is associated with pre-eclampsia. *Mol Hum Reprod.* 2005; 11: 437-440.
18. Kubaszek A, Pihlajamäki J, Komarovski V, Lindi V, Lindström J, Eriksson J, Valle T, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M, Finnish Diabetes Prevention Study. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. *Diabetes.* 2003; 52: 1872-1876.
19. Pihlajamäki J, Ylinen M, Karhapää P, Vauhkonen I, Laakso M. The effect of the -308A allele of the TNF-alpha gene on insulin action is dependent on obesity. *Obes Res.* 2003; 11: 912-917.
20. Rezaieyazdi Z, Afshari J, Sandooghi M, Mohajer F. Tumour necrosis factor a -308 promoter polymorphism in patients with rheumatoid arthritis. *Rheumatol Int.* 2007.
21. Nemeč P, Pavkova-Goldbergova M, Stouracova M, Vasku A, Soucek M, Gatterova J. Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population. *Clin Rheumatol.* 2007.
22. Reich K, Mössner R, König I, Westphal G, Ziegler A, Neumann C. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. *J Invest Dermatol.* 2002; 118: 155-163.
23. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin J, Humphries S, Woo P. The Effect of Novel Polymorphisms in the Interleukin-6 (IL-6) Gene on IL-6 transcription and Plasma IL-6 Levels, and an Association with Systemic-Onset Juvenile Chronic Arthritis. *J. Clin. Invest.* 1998; 102: 1369-1376.
24. Bennermo M, Held C, Stemme S, Ericsson C, Silveira A, Green F, Tornvall P. Genetic Predisposition of the Interleukin-6 Response to Inflammation: Implications for a Variety of Major Diseases? *Clinical Chemistry.* 2004; 50: 2136-2140.
25. Fernandez-Real J, Vendrell J, Richart C, Gutierrez C, Ricart W. Platelet count and Interleukin 6 Gene polymorphism in healthy subjects. *Bmc Medical Genetics.* 2001; 2: 6.
26. Fernández-Real J, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M, Richart C, Ricart W. Interleukin-6 Gene Polymorphism and Insulin Sensitivity. *Diabetes.* 2000; 47: 517-520.

27. Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen J, Pedersen B. A trauma-like elevation of plasma cytokines in humans in response to treadmill running. *Journal of Physiology* 1998; 513: 889-894.
28. Smith L. Cytokine hypothesis of overtraining: a physiological adaptation excessive stress. *Med Sci Sports Exerc.* 2000; 32: 317-331.
29. Vignaud A, Cebrian J, Martelly I, Caruelle J, Ferry A. Effect of anti-inflammatory and antioxidant drugs on the long-term repair of severely injured skeletal muscle. *Exp Physiol.* 2005.
30. Steinacker J, Lormes W, Reissnecker S, Liu Y. New aspects of the hormone and cytokine response to training. *Eur J Appl Physiol.* 2004; 91: 382-391.
31. Christiansen L, Bathum L, Andersen-Ranberg K, Jeune B, Christensen K. Modest implication of interleukin-6 promoter polymorphisms in longevity. *Mech Ageing Dev.* 2004; 125: 391-395.
32. Bonafè M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, Pieri C, Marra M, Antonicelli R, Lisa R, Rizzo M, Paolisso G, Monti D, Franceschi C. A gender-dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. *Eur J Immunol.* 2001; 31: 2357-2361.
33. Hurme M, Lehtimäki T, Jylhä M, Karhunen P, Hervonen A. Interleukin-6-174G/C polymorphism and longevity: a follow-up study. *Mech Ageing Dev.* 2005; 126: 417-418.
34. Herbert A, Liu C, Karamohamed S, Schiller J, Liu J, Yang Q, Wilson P, Cupples L, Meigs J. The -174 IL-6 GG genotype is associated with a reduced risk of type 2 diabetes mellitus in a family sample from the National Heart, Lung and Blood Institute's Framingham Heart Study. *Diabetologia.* 2005; 48: 1492-1495.
35. Schaaf B, Rupp J, Müller-steinhardt M, Kruse J, Boehmke F, Maass M, Zabel P, Dalhoff K. The interleukin-6-174 promoter polymorphism is associated with extrapulmonary bacterial dissemination in *Streptococcus pneumoniae* infection. *Cytokine.* 2005; 31: 324-328.
36. Testa R, Olivieri F, Bonfigli A, Sirolla C, Boemi M, Marchegiani F, Marra M, Cenerelli S, Antonicelli R, Dolci A, Paolisso G, Franceschi C. Interleukin-6-174 G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. *Diabetes Res Clin Pract.* 2006; 71: 299-305.
37. Nicklas B, Mychaleckyj J, Kritchevsky S, Palla S, Lange L, Lange E, Messier S, Bowden D, Pahor M. Physical function and its response to exercise: associations with cytokine gene variation in older adults with knee osteoarthritis. *J Gerontol A Biol Sci Med Sci.* 2005; 60: 1292-1298.
38. Garrote J, Arranz E, Gómez-González E, León A, Farré C, Calvo C, Bernardo D, Fernández-Salazar L, Blanco-Quirós A. IL6, IL10 and TGFB1 gene polymorphisms in celiac disease: differences between DQ2 positive and negative patients. *Allergol Immunopathol (Madr).* 2005. 33: 245-249.
39. Libra M, Signorelli S, Vevelacqua Y, Navolanic P, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino M, Malaponte G. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. *J Clin Pathol.* 2006; 59: 211-215.
40. Koivisto A, Helisalmi S, Pihlajamäki J, Moilanen L, Kuusisto J, Laakso M, Hiltunen M, Keijo K, Hänninen T, Helkala E, Kervinen K, Kesäniemi Y, Soininen H. Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population. *J Neurogenet.* 2005; 19: 155-161.

41. Capurso C, Solfrizzi V, D'Introno A, Colacicco A, Capurso S, Capurso A, Panza F. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease; geographic allele and genotype variations in Europe. *Exp Gerontol.* 2004; 39: 1567-1573.
42. Villuendas G, San Millán J, Sancho J, Escobar-Morreale H. The -597 G-> C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. *J Clin Endocrinol Metab.* 2002; 87: 1134-1141.
43. Rivera-Chavez F, Peters-Hybki D, Barber R, O'Keefe G. Interleukin-6 Promoter Haplotypes and Interleukin-6 Cytokine Responses. *Shock.* 2003; 20: 218-223.
44. Chung H, Seo J, Hur S, Kim H, Kim J, Jung J, Kim L, Park B, Shin H. Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women. *J Hum Genet.* 2003; 48: 243-248.
45. Dhamrait S, James L, Brull D, Myerson S, Hawe E, Pennell D, World M, Humphries S, Haddad F, Montgomery H. Cortical bone resorption during exercise is interleukin-6 genotype-dependent. *Eur J Appl Physiol.* 2003; 89: 21-25.
46. Moffett S, Amuda J, Cauley J, Stone K, Nevitt M, Ensrud K, Hillier T, Hochberg M, Joslyn G, Morin P, Cummings S, SOF Research Group. *J Bone Miner Res.* 2004; 19: 1612-1618.
47. Ferrari S, Karasik S, Liu J, Karamohamed S, Herbert A, Cupples L, Kiel D. Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study. *J Bone Miner Res.* 2004; 19: 552-559.
48. Ferrari S, Garnerio P, Emond S, Montgomery H, Humphries S, Greenspan S. A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women. *Arthritis Rheum.* 2001; 44: 196-201.
49. Rivera-Chavez F, Peters-Hybki D, Barber R, O'Keefe G. Interleukin-6 Promoter Haplotypes and Interleukin-6 Cytokine Responses. *Shock.* 2003; 20: 218-223.

MnSOD References

1. Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J, Albanes D. Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). *Cancer Causes Control.* 2003; 14: 513-518.
2. Millikan RC, Player J, Rene de Cotret A, Moorman P, Pittman G, Vannappagari V, Tse C-K J, Keku T. Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites.
3. Gottlieb MG, Schwanke CH, Santos AF, Jobim PF, Mussel DP, da Cruz IB. Association among oxidized LDL levels, MnSOD, apolipoprotein E polymorphisms, and cardiovascular risk factors in a south Brazilian region population. *Genet. Mol. Res.* 2005; 4: 691-703.
4. Genkinger JM, Platz EA, Hoffman SC, Strickland P, Huang HY, Comstock GW, Helzlsouer KJ. C47T polymorphism in manganese superoxide dismutase (MnSOD), antioxidant intake and survival. *Mech. Ageing Dev.* 2006; 127: 371-377.
5. Holla LI, Kankova K, Vasku A. Functional polymorphism in the manganese superoxide dismutase (MnSOD) gene in patients with asthma. *Clin. Biochem.* 2006; 39: 299-302.

6. Park SY, Lee KH, Kang D, Lee KH, Ha EH, Hong YC. Effect of genetic polymorphisms of MnSOD and MPO on the relationship between PAH exposure and oxidative DNA damage. *Mutat. Res.* 2006; 593: 108-115.
7. Cai Q, Shu X, Wen J, Dai Q, Gao Y, Zheng W. Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. *Breast Cancer Res* 2004; 6: R647-R655.
8. Gottlieb M, Schwanke C, Santos A, Jobim P, Müssel, da Cruz I. Association among oxidized LDL levels, MnSOD, apolipoprotein E polymorphisms, and cardiovascular risk factors in a south Brazilian region population. *Genetics and Molecular Research.* 2005;4: 691-703.
9. Ambrosone C, Freudenheim J, Thompson P, Bowman E, Vena J, Marshall J, Graham S, Laughlin R, Nemoto T, Shields P. Manganese Superoxide Dismutase (MnSOD) genetic Polymorphisms, Dietary Antioxidants, and Risk of Breast Cancer. *Cancer Research.* 1999; 59: 602-606.
10. Genkinger J, Platz E, Hoffman S, Comstock G, Helzlsouer K. Fruit, vegetable, and antioxidant intake and all-cause, cancer, and cardiovascular disease mortality in a community-dwelling population in Washington County, Maryland. *Am J Epidemiol.* 2004 15; 160: 1223-1233.
11. Tikly M, Marshall S, Haldar N, Gulumian M, Wordsworth P, Welsh K. Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis. *Free Radic Biol Med.* 2004; 36: 1403-1407.
12. Gottlieb M, Schwanke C, Santos A, Jobim P, Mussel D, da Cruz I. Association among oxidized LDL levels, MnSOD, apolipoprotein E polymorphisms, and cardiovascular risk factors in a south Brazilian region population. *Genet Mol Res.* 2005; 4: 691-703.
13. Woodson K, Tangrea J, Lehman T, Modali R, Taylor K, Syder K, Taylor P, Virtamo J, Albanes D. Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). *Cancer Causes Control.* 2003; 14: 513-518.
14. Park S, Lee K, Kang D, Lee k, Ha E, Hong Y. Effect of genetic polymorphisms of MnSOD and MPO on the relationship between PAH exposure and oxidative DNA damage. *Mutat Res.* 2006; 593: 108-115.
15. Tamimi R, Hankinson S, Spiegelman D, Colditz G, Hunter D. Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2004; 13: 989-996.
16. Han J, Colditz G, Hunter D. Manganese superoxide dismutase polymorphism and risk of skin cancer (United States). *Cancer Causes Control.* 2007; 18: 79-89.
17. Bergman M, Ahnström M, Palmebäck Wegman P, Wingren S. Polymorphism in the manganese superoxide dismutase (MnSOD) gene and risk of breast cancer in young women. *J Cancer Res Clin Oncol.* 2005; 131: 439-444.
18. Kocabaş N, Sardaş S, Cholerton S, Daly A, Elhan A, Karakaya A. Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility. *Cell Biochem Funct.* 2005; 23: 73-76.
19. Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, Degoul F. The manganese superoxide dismutase Ala 16Val dimorphism modulates both mitochondrial import and mRNA stability. *Pharmacogenet Genomics.* 2005; 15: 311-319.
20. Genkinger J, Platz E, Hoffman S, Strickland P, Huang H, Comstock G, Helzlsouer K. C47T polymorphism in manganese superoxide dismutase (MnSOD), antioxidant intake and survival. *Mech Ageing Dev.* 2006; 127: 371-377.

21. Holla L, Kankova K, Vasku A. Functional polymorphism in the manganese superoxide dismutase (MnSOD) gene in patients with asthma. *Clin Biochem.* 2006; 39: 299-302.

CYP1A1, GSTP1, GSTT1 & GSTM1 References

1. Colombo J, Rossit A, Caetano A, Borim A, Wohnrath D, Silva E. GSTT1, GSTM1 and CYP2E1 genetic polymorphisms in gastric cancer and chronic gastritis in a Brazilian population. *World J. Gastroenterol.* 2004; 10: 1240-1245.
2. Kote-Jarai Z, Easton D, Edwards S, Jefferies S, et al. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset of prostate cancer.
3. Ballerini S, Bellincampi L, Bernardini S, Iori R, Cortese C, Federici G. Analysis of GSTP1-1 polymorphism using real-time polymerase chain reaction. *Clinica. Chimica. Acta.* 2003; 329: 127-132.
4. Kiyohara C, Wakai K, Mikami H, Sido K, Ando M, Ohno Y. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case control study in Japanese non-smoking women. *Int. J. Cancer.* 2003; 107: 139-144.
5. Ghobadloo SM, Yaghmaei B, Bakayev V, Goudarzi H, Noorinayer B, Samiy S, Aghabozorgi S, Zali MR. GSTP1, GSTM1 and GSTT1 genetic polymorphisms in patients with cryptogenic liver cirrhosis. *J. Gastrointest. Surg.* 2004; 8: 423-427.
6. Tamer L, Calikoglu M, Ates NA, Yildirim H, Ercan B, Saritas E, Unlu A, Atik U. Glutathione-S-transferase gene polymorphisms (GSTT1, GSTM1 and GSTP1) as increased risk factors for asthma. *Respiratory.* 2004; 9: 493-498.
7. Nebert DW, McKinnon RA, Puga A. Human drug-metabolising enzyme polymorphisms: effects on risk of toxicity and cancer. *DNA and Cell Biology.* 1996; 15: 273-280.
8. Delescluse C, Lemaire G, de Sousa G, Rahmani R. Is CYP1A1 induction always related to AHR signaling pathway? *Toxicology.* 2000; 153: 73-82.
9. Tamer L, Calikoglu M, Ates N, Yildirim H, Ercan B, Saritas E, Unlu A, Atik U. Glutathione-S-transferase gene polymorphisms (GSTT1, GSTM, GSTP1) as increased risk factors for asthma. *Respirology.* 2004; 9: 493-498.
10. Ghobadloo S, Yaghmaei B, Bakayev V, Goudarzi H, Noorinayer B, Rah F, Samiy S, Aghabozorgi S, Zali M. GSTP1, GSTM1, and GSTT1 genetic polymorphisms in patients with cryptogenic liver cirrhosis. *J Gastrointest Surg.* 2004; 8: 423-427.
11. Evans A, Henner W, Eilers K, Montalto M, Wersinger E, Andersen P, Cohen J, Everts E, McWilliams J, Beer T. Polymorphisms of GSTT1 and related genes in head and neck cancer risk. *Head Neck.* 2004; 26: 63-70.
12. Chen C, Liu Q, Relling M. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. *Pharmacogenetics.* 1996; 6: 187-191.

Disclaimer

All rights reserved. No parts of this work may be reproduced in any form or by means – graphics, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems – without the written permission of the publisher.

Products that are referred to in this document may be either trademarks and/or registered trademarks of the respective owners. The publisher and the author make no claim to these trademarks.

While every precaution has been taken in the preparation of this document, the publisher and the author assume no responsibility for errors or omissions, or for damages resulting from the use of information contained in this document. In no event shall the publisher and the author be liable for any loss of profit, any commercial or personal damage caused or alleged to have been caused directly or indirectly by this document.

Printed: November 2007

© Excelgene Pty Ltd 2007